Related Experiment Video
Updated: Sep 27, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia
Hooriyeh Shapoorian1, Hamidreza Zalpoor2, Mazdak Ganjalikhani-Hakemi1,3
1Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:
In general, acute myeloid leukemia (AML) is an aggressive and heterogeneous disease that is characterized by rapid cellular proliferation and high mortality. One of the mutations related to AML is the Flt3-ITD mutation, which is found in approximately 25% of patients. In this mini-review, we investigate the function of dendritic cells and T cells based on Flt3-ITD mutation and immune evasion as a result of this abnormality. Finally, we discuss some AML therapeutic strategies, including targeting Flt3 on DCs and TIM-3 on T cells as immune receptors to treat this hematopoietic malignancy.
Insights
This review explores how the Flt3-ITD mutation in acute myeloid leukemia (AML) affects immune cells. It discusses immune evasion and potential therapies targeting Flt3 and TIM-3.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Acute myeloid leukemia (AML) is an aggressive cancer with high mortality.
- The Flt3-ITD mutation occurs in about 25% of AML patients.
- This mutation impacts immune cell function and promotes immune evasion.
Purpose of the Study:
- To investigate dendritic cell (DC) and T cell function in AML with Flt3-ITD.
- To understand immune evasion mechanisms driven by the Flt3-ITD mutation.
- To explore novel therapeutic strategies for AML.
Main Methods:
- Review of existing literature on Flt3-ITD in AML.
- Analysis of immune cell (dendritic cells and T cells) function.
- Discussion of immune evasion pathways.
Main Results:
- The Flt3-ITD mutation alters DC and T cell functions.
- This alteration contributes to immune evasion in AML.
- Targeting Flt3 on DCs and TIM-3 on T cells shows therapeutic potential.
Conclusions:
- Flt3-ITD is a key factor in AML immune evasion.
- Targeting Flt3 and TIM-3 represents promising therapeutic avenues for AML.
- Further research into immune-based therapies for AML is warranted.
